title: Role of the tumor microenvironment in mature B-cell lymphoid malignancies.
abstract: The tumor microenvironment is the cellular and molecular environment in which the tumor exists and with which it continuously interacts. In B-cell lymphomas, this microenvironment is intriguing in that it plays critical roles in the regulation of tumor cell survival and proliferation, fostering immune escape as well as the development of treatment resistance. The purpose of this review is to summarize the proceedings of the Second Annual Summit on the Immune Microenvironment in Hematologic Malignancies that took place on September 11-12, 2014 in Dublin, Ireland. We provide a timely overview of the composition and biological relevance of the cellular and molecular microenvironment interface and discuss the role of interactions between the microenvironment and neoplastic cells in a variety of B-cell lymphomas. In addition, we focus on various novel therapeutic strategies that target the tumor microenvironment, including agents that modulate B-cell receptor pathways and immune-checkpoints, chimeric antigen receptor T cells and immunomodulatory agents.
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA nfowler@mdanderson.org.
authors.forename: Nathan H
authors.initials: NH
authors.lastname: Fowler
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Haematology, Pathwest Laboratory Medicine WA and Sir Charles Gairdner Hospital, Perth, Western Australia University of Western Australia, Perth, Canada.
authors.forename: Chan Yoon
authors.initials: CY
authors.lastname: Cheah
authors.affiliation: British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
authors.forename: Randy D
authors.initials: RD
authors.lastname: Gascoyne
authors.affiliation: Department of Haemato-Oncology, Barts Cancer Institute, London, UK.
authors.forename: John
authors.initials: J
authors.lastname: Gribben
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Sattva S
authors.initials: SS
authors.lastname: Neelapu
authors.affiliation: Università Vita-Salute San Raffaele, Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele, Milan, Italy Department of Onco-Hematology, Ospedale San Raffaele, Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Ghia
authors.affiliation: Children's Research Institute, Washington, DC, USA.
authors.forename: Catherine
authors.initials: C
authors.lastname: Bollard
authors.affiliation: Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Ansell
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Curran
authors.affiliation: Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
authors.forename: Wyndham H
authors.initials: WH
authors.lastname: Wilson
authors.affiliation: University of California, Irvine, CA, USA.
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.affiliation: St. James' Hospital, Dublin, Ireland.
authors.forename: Cliona
authors.initials: C
authors.lastname: Grant
authors.affiliation: Cancer Therapeutic Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Little
authors.affiliation: University of Heidelberg, Germany.
authors.forename: Thorsten
authors.initials: T
authors.lastname: Zenz
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Loretta J
authors.initials: LJ
authors.lastname: Nastoupil
authors.affiliation: Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
authors.forename: Kieron
authors.initials: K
authors.lastname: Dunleavy
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D015415:Biomarkers; D019008:Drug Resistance, Neoplasm; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007167:Immunotherapy; D015448:Leukemia, B-Cell / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology* / Q000628:therapy; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology* / Q000628:therapy; D058990:Molecular Targeted Therapy; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D015398:Signal Transduction; D019139:Tumor Escape / Q000276:immunology; D059016:Tumor Microenvironment / Q000187:drug effects / Q000276:immunology
chemical_list: D015415:Biomarkers